Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I don't think Muscle Pharm went bust. They sold $30 mil product in the first 6 months of 2012.
I want an update on this: A Non-Disclosure Agreement has been signed with a major equipment supplier to the wireless telecomm industry, and another one is in process with a major wireless telecomm carrier. $AFPW
Thanks, I haven't had to do the phone order. Someone last week said TDA charged for it.
Go to the DTC site. TDA just wants to charge you for called in orders. Did they tell you that?
That was answered last week. It's not DTC unless you pull it from DTC site.
I use ETrade. No problem.
He should at least know who he sold to. That's not a hard question. I'm holding too.
Some brokers just won't let you trade penny stocks online.
NOT TRUE - show your prove from DTC
Did you ask him about the Barclay Group majority owner?
Actual mining with profits trumps estimates anytime.
The fact that Andes has its own mill means that it is not dependent on other producers to process its ore. It is always able to generate a cash flow because it does not have to wait for other mills to process its ore. $AGCZ
First, are the reserves proven? For Andes Gold, we don't consider reserves 'proven' until our mining efforts have reached the gold and we've had an assay study done showing us the concentration of gold, its purity, and the extent of the vein. Many companies out there proclaim to have found gold but are, in fact, several years away from reaching that gold, let alone proving the value and extent of the find.
"Second, and just as import, the gold must be economically viable to extract. Again, we've seen claims of massive gold reserves when in reality, the cost to mine and process the gold is greater than its value. An investor should always ask the relevant question: how much gold per ton is being extracted. At Andes Gold, our average is one ounce of gold per ton of aggregate. What this means is that we can extract and process our gold profitably." $AGCZ
$AGCZ - Grass Roots Research (GRRD) Wall Streets leading independent micro-cap research firm announced that it has initiated coverage of AGCZ (PINKSHEETS: AGCZ) with a BUY recommendation and a 12 month price target of $0.083 per share. GRRD provides an in-depth analysis, including 5 year financial and evaluation projections, on AGCZ's plan and its significant growth drivers. Acopy of the report is available for download at http://www.grassrootsrd.com.
You are so very welcome.
Hi Seeker. Is Joe gone and we are left alone? If he is, I don't think Eric has the money to start a new business.
$AGCZ - Andes GOLD on youtube:
$AGCZ - Andes Gold Corp's website:
http://www.andesgoldmine.com/
Andes Gold Corporation Adds Milling Capacity Through Purchase in Peru
Andes Gold Corporation (PINKSHEETS: AGCZ), a gold mining company with existing operations in Ecuador, is pleased to announce that it has purchased a second mill in Peru with a capacity of 20 tons per day. The Company expects to upgrade this mill to a capacity of 40 tons per day. With the upgrades the Company will have an overall milling capacity of 90 tons per day in Peru. The Company has 2 producing gold mines and 3 fully operating mills/smelters. At capacity, the mills can produce 240 tons per day with a projected average head grade of 1.0 oz of gold per ton. $AGCZ
$AGCZ - The Company has 2 producing gold mines and 3 fully operating mills/smelters. At capacity, the mills can produce 240 tons of ore per day. During the last half of the year, the company will continue to expand its daily production, extraction and milling operations with output increasing every day. Andes is ideally positioned to show significant growth over the rest of 2012. $AGCZ
$AGCZ - On the balance sheet, the Company reported assets of $4,054,872 and liabilities including amounts due to related parties of $1,057,211 yielding a 3.8 to 1 asset to debt rate.
$AGCZ - The financial report for the six (6) months ended June 30, 2012 shows total revenues of $2,793,923 compared to revenues of $1,824,363 for the six months ended June 30, 2011. This is an increase of $960,560 or 53% over the prior year. Net profits for the six (6) month period ended June 30, 2012 were $481,871 compared to $265,303 last year. This represents an increase in profits of 81.6%. The profit for the year ended December 31, 2011 was $521,294 versus a profit at six months of $481, 871. $AGCZ
AGCZ owns two producing mines and one fully operating mill. The mill is currently processing 50 tons of ore per day. The average head grade of ore being processed is 1.0 Oz gold and 15g of silver per ton of ore. On the Miranda vein, the company has 95,000 oz. of proven reserves. Inferred reserves from the 700m level on Miranda, Azul, Estrella, Sul and Viscaya veins are 600,000 oz. $AGCZ
Andes Gold Corporation Intersects Seven New Veins
Andes Gold Corp. (PC) (USOTC:AGCZ)
Andes Gold Corporation (PINKSHEETS: AGCZ), a gold mining company with existing operations in Ecuador, is pleased to announce that it has intersected 7 new veins on one of its concessions. Of the veins intersected, 4 of them contain gold and sulphides and 3 of them contain copper ranging from 3 to 4%. The Company is currently having samples evaluated at independent labs.
AGCZ - wholly owned subsidiary company Compania Minera PLS.A. In Ecuador, (South America) which controls a Gold mining and exploration concession called the Miranda Alto.
"The company's focus has been to build from our solid base operation at the Miranda mine and grow in a logical well planned direction, the new acquisitions of the Confraternidad Concession for a 5% stake along with the Roman Mine are important steps for our long term future growth,"
Miranda - Sorocha and Estralla veins in the Carretera tunnel
Andes Gold Corporation. (PINKSHEETS: AGCZ) announced today that it has found a 15% higher gold concentration at its new Roman Mine.
The company is pleased to announce that the exploratory crews who have been advancing at 4.5 meters per day intersecting the Azul vein which is showing 50 cmt wide and producing at 9 grams per ton of gold.
Another oldie for you, I thought maybe you would like to see it.
Does that make their research wrong? I don't think so! How long do you think they would be in business if they didn't do good research. And who would pay for their reports if they were wrong? I see that it won't matter to you what kind of research or assay reports come out on AGCZ, you will discredit them.
NBC NEWS REPORTS THAT CANNABIDIOL (CBD) "TURNS OFF" THE CANCER GENE INVOLVED IN METASTASIS FINDINGS BY SCIENTISTS AT CALIFORNIA PACIFIC MEDICAL CENTER GIVES SCIENTIFIC SUPPORT FOR CANNABIS SCIENCE INITIATIVES
1:45 PM ET 9/20/12 | BusinessWire
Cannabis Science (CBIS), a pioneering U.S. Biotech Company developing pharmaceutical products for global public health challenges, reports on a recent press release by the San Francisco NBC news, with new studies by Scientists at California Pacific Medical Center, which have shown that cannabidiol, (CBD), has the ability to "turn off" a gene that causes breast and other types of cancers to metastasize, according to the San Francisco Chronicle newspaper.
NBC News reports, "The drug "has been shown to reduce pain and nausea" in cancer patients. AIDS patients also use cannabis to eat, sleep and otherwise be more functional. Turns out that cannabidiol has none of the psychotropic effects of marijuana as a whole. The researchers hope to move to clinical trials on humans soon to test the cannabidiol inhibition of metastasis, reported in the San Francisco Chronicle. "What they found is that the cannabinoid turns off the overexpression of ID-1, which makes the cells lose their ability to travel to distant tissues. In other words, it keeps the cells more local and blocks their ability to metastasize. (spread to a new location) The researchers stressed cannabidiol works only on cancer cells that have these high levels of ID-1 and these do not include all cancerous tumors but, rather, aggressive, metastatic cells. But they've found such high levels in leukemia, colorectal, pancreatic, lung, ovarian, brain and other cancers."
Cannabis Science appreciates this additional scientific support that this report provides for our two target drug development programs as the Company moves forward with CS-TATI-1, and based on the success of previous skin cancer patients who self-administered cannabis-based treatments, the Company is focusing on the use of CS-S/BCC-1 topical cannabis-based preparations for the treatment of basal and squamous cell carcinomas.
Dr. Robert Melamede states, "Cannabis Science is excited for the increasing scientific support for our projects. In the near future, we will share new developments, as well a the progress we have made with our earlier defined initiatives. Our professional expansion and development, as detailed in our latest news releases,was driven by the science of how cannabinoids can benefit both HIV/AIDS and Cancer Patients."
NBC News: http://www.msnbc.msn.com/id/49094732#.UFsvfY7nuZY
San Francisco Chronicle: http://www.sfgate.com/health/article/Pot-compound-seen-as-tool-against-cancer-3875562.php#page-1
About CS-S/BCC-1
Cannabis Science is currently working with CBR International to develop a Pre-IND Application to the FDA that focuses on the use of CS-S/BCC-1 topical cannabis-based preparations for the treatment of basal and squamous cell carcinomas. Cannabis Science has already seen success with 4 self-medicated skin cancer patients. These patients have been self-administering using cannabis-based extracts applied topically to their carcinomas and tumors. These patients have experienced shrinking and apparent eradication of their skin cancer, backed by positive reports from their doctors, which is why the Company is confident about the eminent success of this new drug to be developed.
About CS-TATI-1
Data published in March by researchers at the Mount Sinai School of Medicine found that cannabinoids inhibit TAT induced migration to TAT via cannabinoid 2 receptors (CB2). Funding for the Mount Sinai study was provided by a National Institutes of Health (NIH) Clinical and Translational Science Award Grant. Cannabis Science's research of CS-TATI-1 will be targeted to newly diagnosed patients infected with drug resistant virus, treatment experienced patients with drug-resistant HIV strains, and those intolerant of currently available therapies. Cannabis Science will be pursuing a wide range of NIH based Federal Research Programs such as RO1's, PO1's and SBIRS which exist to support preclinical development of target validation and proof of concept studies. Cannabis Science will be pursing implementation of these studies through collaborations with leading scientific institutions. Cannabis Science will also be pursuing other clinical research collaborations including the AIDS Clinical Trials Groups (ACTG), the Canadian AIDS Trial Network (CATN) and the European AIDS Trial Network (EATN).
About Cannabis Science, Inc.
Cannabis Science, Inc. is conducting cannabinoid research and development for several critical ailments. The Company is currently developing two formulation drugs for critical ailments, Skin Cancer and HIV/AIDS. The Company works with leading experts in new drug development, medicinal characterization, and clinical research to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. Cannabis Science is currently working with CBR International to develop a Pre-IND Application to the FDA that focuses on the use of CS-S/BCC-1 topical cannabis-based preparations for the treatment of basal and squamous cell carcinomas. Preclinical development of CS-TATI-1 appears to inhibit HIV associated Kaposi Sarcoma by inhibiting HIV Tat. This cancer is significant threat to people with HIV. HIV Tat protein appears to trans activate Kaposi sarcoma. The inhibition of HIV Tat offers a promising new approach to inhibiting KSHV infective cycle.
Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
SOURCE: Cannabis Science
View data
Cannabis Science Inc. Dr. Robert J. Melamede President & CEO 1-888-889-0888 info@cannabisscience.com www.cannabisscience.com or Robert Kane VP Investor Relations 1-561-234-6929 rkane@cannabisscience.com info@cannabisscience.com www.cannabisscience.com
Yes, I guess a 3 to 6 month old report just doesn't apply any more.
https://commerce.us.reuters.com/purchase/showReportDetail.do?docid=59964108
Andes Gold Corporation (AGCZ) thorough analysis of company operations, products, market, competitors. Several case forecasts, valuation, price targets and more
Price:
$368.00
Provider:
Cohen Independent Research Group
Date:
26 Jun 2012
Pages:
43
Type:
AcrobatPDF
Companies referenced:
AGCZ.PK
Available for Immediate Download
Summary:
Andes Gold Corporation (OTC Pink: AGCZ), through its wholly owned subsidiary Compaqia Minera P.L. controls a Gold mining and exploration concession called the Miranda Alto in Ecuador, South America. Andes Gold owns two producing gold mine and one fully operations mill/ smelter in Ecuador. In addition, recently AGCZ completed a new 50 ton per day mill in Peru. The Company is aggressively expanding exploration at its existing leases, acquiring additional leases with established gold reserves and leveraging additional capacities at its operating mills to process gold from other gold mines. Andes Gold is currently producing approximately 50 ounces per day on concessions located in the cantons of Zaruma and Portovelo, province of El Oro, located in southern Ecuador (together referred as Miranda Alto concessions). These two mines together have proven gold reserves of approximately 395,000 ounces of gold. The gold and silver ore produced from these concessions are processed in the Company owned Zaruma Mill, a fully functional processing mill with a processing capacity of 170 tons per day. The additional capacity at Zaruma Mill allows the Company to process ore from neighbouring mines as well, resulting in higher cash flows. Further, the addition of 50 ton per day mill in Peru will result in additional processing revenues for the Company and will allow it to expand into the attractive gold mining industry in Peru. Quality assets, excellent cash position, superior business model, experienced management and attractive gold market dynamics are all contributors to future success. Our conservative estimates forecast revenues to grow from $4.45 million in FYE December 31, 2011 to approximately $122.94 million by FYE 2018. Based on these projections the Cohen Target Price is 150.2% higher than the current price.
$AGCZ - MovingPennies Newsletter
MovingPennies.com Hello Traders! Yes we know all of you have seen a million gold companies and your probably wondering why you should care about this one. Well I will tell you the main difference. Most of these other companies you hear about are in the exploration stage. This means they have not even found gold yet.
Andes Gold Mine – AGCZ is what we refer to as a producer. This means they have already found gold and are actually mining gold right now! AGCZ is mining at a rate of 50oz per day and is extremely focused on increasing its milling capacity as well.
50oz multiplied by the current price of gold ($1690/oz) = $84,500 a day! That is why we are able to say this company is a huge step above its competition! AGCZ – Andes Gold Corporation First things first, this chart is really something. Take a look for your self.
ACGZ is showing many signs of a breakout and even broke through a major resistance point yesterday! Andes Gold Corporation (AGCZ), through its wholly owned subsidiary company Compania Minera P.L., controls a gold mining and exploration concession called the Miranda Alto.
“At the moment, we are processing 50 tonnes a day of ore from two different shafts” The company is currently extracting ore from three different veins, and with new acquisitions rumored to be on the way, the company could soon double production after raising more capital to improve the capacity of the processing plant.
* They are even projecting 250oz. milling production per day by the end of 2012! * Andes Gold owns two producing mines and one fully operating mill.
* The mill is currently processing 50 tonnes of ore per day * The average head grade of ore being processed is 1.0 oz gold and 15g of silver per tonne of ore.
* On the Miranda vein, the company has 95,000 oz. of proven reserves.
Inferred reserves from the 700 m level on Miranda, Azul, Estrella, Sul and Viscaya veins are 600,000 oz AGCZ`s Tunnel Based on the website, images, and prior statements from management, you will see that AGCZ has been building a huge, 1600 meter long mining tunnel that is nearing completion.
* Preliminary estimates indicate that, upon completion, the tunnel will allow access to an additional 700,000 ounces in proven reservesthats $1.1B in new reserves.
Once the tunnel is complete, and the gold reserves verified, production can start immediately. Management indicates that this normally happens within hours of the discovery.
A Changing Industry & Ecuador The gold mining extraction industry is in a transition phase. Because of the increase of gold prices, the industry is making high profits, and Ecuador is taking advantage of this situation. The relevance of gold mining in the country is demonstrated by its placement as the fourth most important with regards to Ecuadorian GDP.
AGCZ`s property lies on the western flank of the Cordillera Occidental of Andes mountain range. The mine is strategically located close to two medium-sized mining towns: Zaruma and Portovela.
The hills of Zaruma and Portovelo have been mined for gold and silver for centuries. The Incas were already extracting gold and silver in the area with hydraulic mining of the oxidized parts of veins when Mercadillo, one of Pizzarros force, followed the Rio Amarillo River upstream and encountered the Inca mine and founded the town of Zaruma in 1549.
Recent News:
Andes Gold Corp Discusses Current Mining Operations, Projections for the Future 3/25/12 Andes Gold Corp, a gold mining company with existing operations in Ecuador, today discussed the Company`s current operations and projected what can be expected in the coming months.
The Company is currently mining its gold concessions located in southern Ecuador. This consists of two mines having proven gold reserves of approximately 395,000 ounces of gold. At today`s prices, that represents a value of over $600M in potential revenue based on an average price per ounce of $1650. The Company`s present mining efforts extract and process approximately 50 ounces per day with an immediate goal of increasing that to 100 ounces of gold per day.
Read the full report [1]Here Let us say that again just in case you missed it. We are talking about Potential Revenues of over $600M dollars based on the estimated amount of gold in these mines. That is an amazing figure.
Feel free to check out [2]AGCZ`s web site as well. There is lots of good information on this company.
Good Luck! -MP Big Winners for 2012:
http://investorshub.advfn.com/boards/post_new.aspx?board_id=10923
Marijuana Fights Cancer and Helps Manage Side Effects, Researchers Find
Sep 6, 2012 4:45 AM EDT
Mounting evidence shows ‘cannabinoids’ in marijuana slow cancer growth, inhibit formation of new blood cells that feed a tumor, and help manage pain, fatigue, nausea, and other side effects.
Cristina Sanchez, a young biologist at Complutense University in Madrid, was studying cell metabolism when she noticed something peculiar. She had been screening brain cancer cells because they grow faster than normal cell lines and thus are useful for research purposes. But the cancer cells died each time they were exposed to tetrahydrocannabinol (THC), the principal psychoactive ingredient of marijuana.
Instead of gaining insight into how cells function, Sanchez had stumbled upon the anti-cancer properties of THC. In 1998, she reported in a European biochemistry journal that THC “induces apoptosis [cell death] in C6 glioma cells,” an aggressive form of brain cancer.
Subsequent peer-reviewed studies in several countries would show that THC and other marijuana-derived compounds, known as “cannabinoids,” are effective not only for cancer-symptom management (nausea, pain, loss of appetite, fatigue), they also confer a direct antitumoral effect.
A team of Spanish scientists led by Manuel Guzman conducted the first clinical trial assessing the antitumoral action of THC on human beings. Guzman administered pure THC via a catheter into the tumors of nine hospitalized patients with glioblastoma, who had failed to respond to standard brain-cancer therapies. The results were published in 2006 in the British Journal of Pharmacology: THC treatment was associated with significantly reduced tumor cell proliferation in every test subject.
Around the same time, Harvard University scientists reported that THC slows tumor growth in common lung cancer and “significantly reduces the ability of the cancer to spread.” What’s more, like a heat-seeking missile, THC selectively targets and destroys tumor cells while leaving healthy cells unscathed. Conventional chemotherapy drugs, by contrast, are highly toxic; they indiscriminately damage the brain and body.
There is mounting evidence, according to a report in Mini-Reviews in Medicinal Chemistry, that cannabinoids “represent a new class of anticancer drugs that retard cancer growth, inhibit angiogenesis [the formation of new blood cells that feed a tumor] and the metastatic spreading of cancer cells.”
Dr. Sean McAllister, a scientist at the Pacific Medical Center in San Francisco, has been studying cannabinoid compounds for 10 years in a quest to develop new therapeutic interventions for various cancers. Backed by grants from the National Institute of Health (and with a license from the DEA), McAllister discovered that cannabidiol (CBD), a nonpsychoactive component of the marijuana plant, is a potent inhibitor of breast cancer cell proliferation, metastasis, and tumor growth.
In 2007, McAllister published a detailed account of how cannabidiol kills breast cancer cells and destroys malignant tumors by switching off expression of the ID-1 gene, a protein that appears to play a major role as a cancer cell conductor.
The ID-1 gene is active during human embryonic development, after which it turns off and stays off. But in breast cancer and several other types of metastatic cancer, the ID-1 gene becomes active again, causing malignant cells to invade and metastasize. “Dozens of aggressive cancers express this gene,” explains McAllister. He postulates that CBD, by virtue of its ability to silence ID-1 expression, could be a breakthrough anti-cancer medication.
“Cannabidiol offers hope of a non-toxic therapy that could treat aggressive forms of cancer without any of the painful side effects of chemotherapy,” says McAllister, who is seeking support to conduct clinical trials with the marijuana compound on breast cancer patients.
McAllister’s lab also is analyzing how CBD works in combination with first-line chemotherapy agents. His research shows that cannabidiol, a potent antitumoral compound in its own right, acts synergistically with various anti-cancer pharmaceuticals, enhancing their impact while cutting the toxic dosage necessary for maximum effect.
cancer-cells-marijuana-lee
Breast cancer cells killed by CBD on right compared to untreated breast cancer cells on left. (Courtesy Pacific Medical Center)
“Cannabidiol offers hope of a non-toxic therapy that could treat aggressive forms of cancer without any of the painful side effects of chemotherapy.
Investigators at St. George’s University in London observed a similar pattern with THC, which magnified the effectiveness of conventional antileukemia therapies in preclinical studies. THC and cannabidiol both induce apoptosis in leukemic cell lines.
At the annual summer conference of the International Cannabinoid Research Society, held this year in Freiburg, Germany, 300 scientists from around the world discussed their latest findings, which are pointing the way toward novel treatment strategies for cancer and other degenerative diseases. Italian investigators described CBD as “the most efficacious inducer of apoptosis” in prostate cancer. Ditto for cannabidiol and colon cancer, according to British researchers at Lancaster University.
Within the medical science community, the discovery that cannabinoids have anti-tumoral properties is increasingly recognized as a seminal advancement in cancer therapeutics.
http://www.thedailybeast.com/articles/2012/09/06/marijuana-fights-cancer-and-helps-manage-side-effects-researchers-find.html
Marijuana Can Prevent the Spread of Cancer, Researchers Discover
Two scientists at California Pacific Medical Center in San Francisco have found that cannabidiol (CBD), a non-toxic marijuana compound that delivers many of weed's benefits without the high, might stop metastis in aggressive cancer, "potentially altering the fatality of the disease forever."
The pair, molecular biologist Pierre Desprez and researcher Sean McAllister, mixed CBD and cells with high levels of 1D-1, the gene that spreads cancer, in a petri dish. What happened next was a bit of a miracle: 1D-1 cells stopped spreading and returned to normal.
"What we found was that his Cannabidiol could essentially 'turn off' the ID-1," Desprez told the Huffington Post.
The duo have been studying CBD's effects on cancer for years, and first published a paper about the finding in 2007. The results just keep getting better.
"We started by researching breast cancer," Desprez told HuffPo, "But now we've found that Cannabidiol works with many kinds of aggressive cancers--brain, prostate--any kind in which these high levels of ID-1 are present."
The finding has already gone through laboratory and animal testing, and is awaiting approval for the real test, a clinical trial in humans. Desprez hopes they can move forward with their research immediately. "We've found no toxicity in the animals we've tested, and Cannabidiol is already used in humans for a variety of other ailments," he told the Huffington Post.
The pair has also been synthesizing CBD in a lab, instead of extracting it from the mairjuana plant, to make it more potent. It is a move that may also help them to avoid red tape from the federal government that still insists marijuana has no medicinal value.
"It's a common practice," explained Desprez. "But hopefully it will also keep us clear of any obstacles while seeking approval."
CBD has been used to help treat seizures, multiple sclerosis, and Alzheimer's.
Smoking marijuana, however, may not deliver enough CBD for it to be effective, the researchers said.
I'm sure that all research and news helps all of us. There's been at least 30 years of research. We need all of it reported in order to change the schedule for more research.
http://www.nbcbayarea.com/news/local/Marijuana-Compound-Fights-Cancer-Human-Trials-Next-170406116.html
A pair of scientists at San Francisco's California Pacific Medical Center Research Institute are preparing to release research data which proves cannabidiol (CBD) - a marijuana compound - has the ability to "turn off" the activity of a gene which causes cancers to metastasize.
"The preclinical trial data is very strong, and there's no toxicity. There's really a lot of research to move ahead with and to get people excited," said Sean McAllister, who along with scientist Pierre Desprez, has been studying the active molecules in marijuana - called cannabinoids - as potent inhibitors of metastatic disease for the past decade, according to an article in the San Francisco Chronicle.
Marijuana is already proven to alleviate nausea and pain related to cancer therapies, but these recent findings indicate a much more vast use for the natural plant which has been vilified by politicians and U.S. laws for decades.
Marijuana a vital tool in fighting many cancers.
Marijuana a vital tool in fighting many cancers.
Photo credit:
Photo by David McNew/Getty Images
McAllister's previous research has shown marijuana has anti-cancer properties as well.
The implications of further scientific research are staggering, yet severely limited, given current federal prohibition of the cannabis plant.
After seeing the initial results of testing cancer cells with the CBD compounds found in marijuana, Desprez and McAllister wondered if they'd made an error, so they repeated the tests again and again, each time receiving the same result: the cancer cells not only stopped acting "crazy" but reverted to a normal, healthy state.
"It took us about 20 years of research to figure this out, but we are very excited," said Desprez to The Huffington Post. "We want to get started with trials as soon as possible."
Desprez hopes the human clinical trials will start without delay.
In an article posted on NBC Bay Area website, "'If this plant were discovered in the Amazon today, scientists would be falling all over each other to be the first to bring it to market,' said Dr. Donald Abrams, chief of oncology at the University of California San Francisco, which has also found science behind marijuana's efficacy."
Marijuana advocates have suspected these truths for decades but have found themselves widely shunned or ignored by U.S. lawmakers.
Dr. T.G., an oncologist who wishes to remain anonymous, told Examiner.com that her practice encourages early-stage cancer patients to use marijuana in an effort to slow cancer progression.
"I've treated patients dealing with cancers for nearly thirty years and I am convinced even consuming cannabis-laced edibles can have a noticeable effect in reduction of cancer cell growth over the long-term. Although cannabis flowers themselves don't contain enough of the CBD component to have the same effects as those in the California study, it is clear intensive research and human trials are warranted," said Dr. T.G. "But it would be much more efficient if all cancer research laboratories could test cannabis and, with federal restrictions on cannabis cultivation, that level of research is not viable."
With healthcare occupying a large segment of the 2012 election focus, President Obama and GOP candidate Mitt Romney may want to consider the continued wisdom of marijuana prohibition.
By publicly calling for marijuana/cannabis to be rescheduled as Schedule II under the Controlled Substances Act of 1970, marijuana will be recognized as having medicinal efficacy and would then be available not only for those 17 states which already have medical marijuana laws in place, but would make the plant available for further clinical research.
Dr. T.G. stated, "In light of emerging evidence and millions of patients who've received benefit from cannabis, there is no logical reason to avoid a federal reversal of prohibition."
It may irritate politicians and prohibitionists nationwide, but it turns out the potheads of the world were right all along...
NBC News Reports that Cannabidiol (CBD) "Turns Off" the Cancer Gene Involved in Metastasis Findings by Scientists at California Pacific Medical Center gives Scientific Support for Cannabis Science Initiatives
1:45 PM ET 9/20/12 | BusinessWire
Cannabis Science (CBIS), a pioneering U.S. Biotech Company developing pharmaceutical products for global public health challenges, reports on a recent press release by the San Francisco NBC news, with new studies by Scientists at California Pacific Medical Center, which have shown that cannabidiol, (CBD), has the ability to "turn off" a gene that causes breast and other types of cancers to metastasize, according to the San Francisco Chronicle newspaper.
NBC News reports, "The drug "has been shown to reduce pain and nausea" in cancer patients. AIDS patients also use cannabis to eat, sleep and otherwise be more functional. Turns out that cannabidiol has none of the psychotropic effects of marijuana as a whole. The researchers hope to move to clinical trials on humans soon to test the cannabidiol inhibition of metastasis, reported in the San Francisco Chronicle. "What they found is that the cannabinoid turns off the overexpression of ID-1, which makes the cells lose their ability to travel to distant tissues. In other words, it keeps the cells more local and blocks their ability to metastasize. (spread to a new location) The researchers stressed cannabidiol works only on cancer cells that have these high levels of ID-1 and these do not include all cancerous tumors but, rather, aggressive, metastatic cells. But they've found such high levels in leukemia, colorectal, pancreatic, lung, ovarian, brain and other cancers."
Cannabis Science appreciates this additional scientific support that this report provides for our two target drug development programs as the Company moves forward with CS-TATI-1, and based on the success of previous skin cancer patients who self-administered cannabis-based treatments, the Company is focusing on the use of CS-S/BCC-1 topical cannabis-based preparations for the treatment of basal and squamous cell carcinomas.
Dr. Robert Melamede states, "Cannabis Science is excited for the increasing scientific support for our projects. In the near future, we will share new developments, as well a the progress we have made with our earlier defined initiatives. Our professional expansion and development, as detailed in our latest news releases,was driven by the science of how cannabinoids can benefit both HIV/AIDS and Cancer Patients."
NBC News: http://www.msnbc.msn.com/id/49094732#.UFsvfY7nuZY
San Francisco Chronicle: http://www.sfgate.com/health/article/Pot-compound-seen-as-tool-against-cancer-3875562.php#page-1
About CS-S/BCC-1
Cannabis Science is currently working with CBR International to develop a Pre-IND Application to the FDA that focuses on the use of CS-S/BCC-1 topical cannabis-based preparations for the treatment of basal and squamous cell carcinomas. Cannabis Science has already seen success with 4 self-medicated skin cancer patients. These patients have been self-administering using cannabis-based extracts applied topically to their carcinomas and tumors. These patients have experienced shrinking and apparent eradication of their skin cancer, backed by positive reports from their doctors, which is why the Company is confident about the eminent success of this new drug to be developed.
About CS-TATI-1
Data published in March by researchers at the Mount Sinai School of Medicine found that cannabinoids inhibit TAT induced migration to TAT via cannabinoid 2 receptors (CB2). Funding for the Mount Sinai study was provided by a National Institutes of Health (NIH) Clinical and Translational Science Award Grant. Cannabis Science's research of CS-TATI-1 will be targeted to newly diagnosed patients infected with drug resistant virus, treatment experienced patients with drug-resistant HIV strains, and those intolerant of currently available therapies. Cannabis Science will be pursuing a wide range of NIH based Federal Research Programs such as RO1's, PO1's and SBIRS which exist to support preclinical development of target validation and proof of concept studies. Cannabis Science will be pursing implementation of these studies through collaborations with leading scientific institutions. Cannabis Science will also be pursuing other clinical research collaborations including the AIDS Clinical Trials Groups (ACTG), the Canadian AIDS Trial Network (CATN) and the European AIDS Trial Network (EATN).
About Cannabis Science, Inc.
Cannabis Science, Inc. is conducting cannabinoid research and development for several critical ailments. The Company is currently developing two formulation drugs for critical ailments, Skin Cancer and HIV/AIDS. The Company works with leading experts in new drug development, medicinal characterization, and clinical research to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. Cannabis Science is currently working with CBR International to develop a Pre-IND Application to the FDA that focuses on the use of CS-S/BCC-1 topical cannabis-based preparations for the treatment of basal and squamous cell carcinomas. Preclinical development of CS-TATI-1 appears to inhibit HIV associated Kaposi Sarcoma by inhibiting HIV Tat. This cancer is significant threat to people with HIV. HIV Tat protein appears to trans activate Kaposi sarcoma. The inhibition of HIV Tat offers a promising new approach to inhibiting KSHV infective cycle.
Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
SOURCE: Cannabis Science
View data
Cannabis Science Inc. Dr. Robert J. Melamede President & CEO 1-888-889-0888 info@cannabisscience.com www.cannabisscience.com or Robert Kane VP Investor Relations 1-561-234-6929 rkane@cannabisscience.com info@cannabisscience.com www.cannabisscience.com
Why is yesterdays news not on IHUB or stickied or anywhere that can be seen?
Loyal, If DeZanger doesn't start reporting, the SEC will suspend trading. They have already suspended over 600. Sixteen were suspended this week. SEC is cracking down on non-reporting companies that they consider high risk for investors or fraudulent shells. I'm in another one that got suspended.
Are you saying that Homestake Mining has mined at the same location as New World Gold?
Cannabis Science Inc., (CBIS) announced the appointment of Ronald Sekura PH.D former Food and Drug Administration (FDA) Research Chemist, Center for Biologics Evaluation and Review as Executive Vice President of Regulatory Affairs of Cannabis Science. Dr. Sekura is the former Chief of the Pharmaceutical and Regulatory Affairs Branch of the Division of AIDS at The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institute of Health (NIH).
VERY KEY for $CBIS
Government-sponsored study destroys DEA’s classification of marijuanahttp://www.rawstory.com/rs/2012/07/03/government-sponsored-study-destroys-deas-classification-of-marijuana/
A government-sponsored study published recently in The Open Neurology Journal concludes that marijuana provides much-needed relief to some chronic pain sufferers and that more clinical trials are desperately needed, utterly destroying the U.S. Drug Enforcement Agency’s (DEA) classification of the drug as having no medical uses.
While numerous prior studies have shown marijuana’s usefulness for a host of medical conditions, none have ever gone directly at the DEA’s placement of marijuana atop the schedule of controlled substances. This study, sponsored by the State of California and conducted at the University of California Center for Medicinal Cannabis Research, does precisely that, driving a stake into the heart of America’s continued war on marijuana users by calling the Schedule I placement simply “not accurate” and “not tenable.”
$CBIS